21:06 , Sep 21, 2017 |  BC Innovations  |  Translation in Brief

Driving CARs into neuroblastoma

In separate studies published in the same July issue of the...
07:00 , Sep 19, 2016 |  BioCentury  |  Emerging Company Profile

Solid CARs

Long-standing doubts about whether CAR T cells would be effective against solid tumors were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso showed no complete or partial responses...
07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Celgene's Juno juggernaut

In just a few months, Celgene Corp .'s long game in hematologic malignancies has become clear: a focus on immuno-oncology. A billion dollar decade-long collaboration with Juno Therapeutics Inc. is the big biotech's most recent...
07:00 , Apr 27, 2015 |  BioCentury  |  Finance

CAR talk

While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer L1 cell adhesion molecule (L1CAM; CD171) Studies in patient samples and mice suggest inhibiting CD171 could help treat pancreatic cancer. In the vasculature...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

Celltrion, Medigene, German Cancer Research Center deal

MediGene exercised an option to acquire an exclusive, worldwide license from the center to develop and commercialize a mAb against L1 cell adhesion molecule ( L1CAM , CD171 ) to treat cancer under a 2006...